FOLH1 and prostate neoplasm: Actually, despite the limited availability of comparative head-to-head studies with [18F]F-PSMA-1007 and [68Ga]Ga-PSMA-11 for prostate tumor staging, several studies have reported that both these tracers can equally identify predominant prostate lesions in patients with intermediate- or high-risk PCa, although the nonurinary excretion of [18F]F-PSMA-1007 may help evaluate lesions near the urinary bladder better than [68Ga]Ga-PSMA-11 [25,26,27].